{"transactions":[{"id":713504,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-08T01:08:32.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":4200,"price":36.134,"value":151762.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse."}],"balance_after":84040,"source":{"system":"sec-edgar","filing":"0001543663-26-000017","document":"wk-form4_1783472909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000017/wk-form4_1783472909.xml","form_type":"4"}},{"id":713503,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-08T01:08:32.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":600,"price":36.021,"value":21612.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse."}],"balance_after":88240,"source":{"system":"sec-edgar","filing":"0001543663-26-000017","document":"wk-form4_1783472909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000017/wk-form4_1783472909.xml","form_type":"4"}},{"id":717686,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-02T22:42:57.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":1530,"price":35.227,"value":53897.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":88840,"source":{"system":"sec-edgar","filing":"0001543663-26-000015","document":"wk-form4_1783032175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000015/wk-form4_1783032175.xml","form_type":"4"}},{"id":717685,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-02T22:42:57.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":2531,"price":34.579,"value":87519.449,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":90370,"source":{"system":"sec-edgar","filing":"0001543663-26-000015","document":"wk-form4_1783032175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000015/wk-form4_1783032175.xml","form_type":"4"}},{"id":717684,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-02T22:42:57.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":739,"price":34.059,"value":25169.601,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":92901,"source":{"system":"sec-edgar","filing":"0001543663-26-000015","document":"wk-form4_1783032175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000015/wk-form4_1783032175.xml","form_type":"4"}},{"id":786635,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-05-08T15:51:08.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":4800,"price":32.4358,"value":155691.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":93640,"source":{"system":"sec-edgar","filing":"0001543663-26-000013","document":"wk-form4_1778255465.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000013/wk-form4_1778255465.xml","form_type":"4"}},{"id":786634,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-05-08T15:51:08.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":4800,"price":30.0732,"value":144351.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":98440,"source":{"system":"sec-edgar","filing":"0001543663-26-000013","document":"wk-form4_1778255465.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000013/wk-form4_1778255465.xml","form_type":"4"}},{"id":825182,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-30T21:38:27.000Z","date":"2026-03-26","kind":"sale","planned":true,"acquired":false,"shares":2558,"price":21.6247,"value":55315.9826,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 26, 2026, a Restricted Stock Unit (\"RSU\") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.91, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":103240,"source":{"system":"sec-edgar","filing":"0001543663-26-000011","document":"wk-form4_1774905421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000011/wk-form4_1774905421.xml","form_type":"4"}},{"id":837641,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:02.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":263,"price":22.0195,"value":5791.1285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.075, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":105798,"source":{"system":"sec-edgar","filing":"0001543663-26-000007","document":"wk-form4_1773784859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000007/wk-form4_1773784859.xml","form_type":"4"}},{"id":837640,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:02.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":1395,"price":21.2451,"value":29636.9145,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":106061,"source":{"system":"sec-edgar","filing":"0001543663-26-000007","document":"wk-form4_1773784859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000007/wk-form4_1773784859.xml","form_type":"4"}},{"id":837639,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:02.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":2387,"price":20.4224,"value":48748.2688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.92 to $20.87, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":107456,"source":{"system":"sec-edgar","filing":"0001543663-26-000007","document":"wk-form4_1773784859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000007/wk-form4_1773784859.xml","form_type":"4"}},{"id":866300,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-03T22:03:53.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":4800,"price":25.1096,"value":120526.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":109843,"source":{"system":"sec-edgar","filing":"0001543663-26-000005","document":"wk-form4_1772575431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000005/wk-form4_1772575431.xml","form_type":"4"}},{"id":884488,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-24T23:49:01.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":131900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 131,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":131900,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":131900},"source":{"system":"sec-edgar","filing":"0001543663-26-000002","document":"wk-form4_1771976938.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000002/wk-form4_1771976938.xml","form_type":"4"}},{"id":884487,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-02-24T23:49:01.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 22,000 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.  Of the remaining shares, 24,000 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":114643,"source":{"system":"sec-edgar","filing":"0001543663-26-000002","document":"wk-form4_1771976938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000002/wk-form4_1771976938.xml","form_type":"4"}},{"id":1188765,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2025-03-29T01:29:40.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":122000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 122,000 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the date of grant with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":122000,"derivative":{"exercise_price":16.14,"expiration_date":"2035-03-26","underlying":"Common Stock","underlying_shares":122000},"source":{"system":"sec-edgar","filing":"0001404644-25-000023","document":"wk-form4_1743211773.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000023/wk-form4_1743211773.xml","form_type":"4"}},{"id":1188764,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2025-03-29T01:29:40.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":20300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 20,300 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":92643,"source":{"system":"sec-edgar","filing":"0001404644-25-000023","document":"wk-form4_1743211773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000023/wk-form4_1743211773.xml","form_type":"4"}},{"id":1203615,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2025-03-17T21:14:56.000Z","date":"2025-03-13","kind":"sale","planned":true,"acquired":false,"shares":4501,"price":16.94,"value":76246.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 12, 2024, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part.  The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person.  The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person.  The sale reported on this Form 4 relates exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.38 to $17.21, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":72343,"source":{"system":"sec-edgar","filing":"0001404644-25-000007","document":"wk-form4_1742246088.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000007/wk-form4_1742246088.xml","form_type":"4"}},{"id":1352551,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2024-11-26T02:29:29.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":24000,"price":20.475,"value":491400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.33 to $20.92, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":76844,"source":{"system":"sec-edgar","filing":"0001404644-24-000113","document":"wk-form4_1732588163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000113/wk-form4_1732588163.xml","form_type":"4"}},{"id":1576491,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2024-03-15T00:53:21.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":53900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":53900,"derivative":{"exercise_price":36.06,"expiration_date":"2034-03-13","underlying":"Common Stock","underlying_shares":53900},"source":{"system":"sec-edgar","filing":"0001404644-24-000008","document":"wk-form4_1710463991.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000008/wk-form4_1710463991.xml","form_type":"4"}},{"id":1576490,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2024-03-15T00:53:21.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":31903,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52844,"source":{"system":"sec-edgar","filing":"0001404644-24-000008","document":"wk-form4_1710463991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000008/wk-form4_1710463991.xml","form_type":"4"}}]}